Cargando…
The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial
OBJECTIVE: Non-adherence to guidelines and preventive measures is a major challenge, particularly so to obtain long-term adherence to lifestyle changes and recommended medication. The objective was to investigate if pictorial information regarding subclinical carotid atherosclerosis provided to indi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387279/ https://www.ncbi.nlm.nih.gov/pubmed/34611639 http://dx.doi.org/10.1016/j.ajpc.2021.100199 |
_version_ | 1783742430064934912 |
---|---|
author | Bengtsson, Anna Norberg, Margareta Ng, Nawi Carlberg, Bo Grönlund, Christer Hultdin, Johan Lindahl, Bernt Lindahl, Bertil Nordin, Steven Nyman, Emma Wennberg, Patrik Wester, Per Näslund, Ulf |
author_facet | Bengtsson, Anna Norberg, Margareta Ng, Nawi Carlberg, Bo Grönlund, Christer Hultdin, Johan Lindahl, Bernt Lindahl, Bertil Nordin, Steven Nyman, Emma Wennberg, Patrik Wester, Per Näslund, Ulf |
author_sort | Bengtsson, Anna |
collection | PubMed |
description | OBJECTIVE: Non-adherence to guidelines and preventive measures is a major challenge, particularly so to obtain long-term adherence to lifestyle changes and recommended medication. The objective was to investigate if pictorial information regarding subclinical carotid atherosclerosis provided to individuals and physicians gave sustained effects on cardiovascular risk beyond the previously reported effect after 1 year and up to 3 years. METHODS: A Prospective Randomized Open Blinded End-point (PROBE) trial. Within a CVD prevention program in Västerbotten County, Sweden, 3532 healthy individuals aged 40, 50 or 60 years were enrolled and 1:1 randomized to intervention (n = 1749; pictorial information with additional prevention materials to participants and physicians) or control group (n = 1783; no pictorial information to participants and physicians). Preventive measures were managed within primary care. Participants were investigated at baseline during 2013–2016 and at follow-up after 1 and 3 years. RESULTS: A beneficial effect on cardiovascular risk was observed at 3-year follow-up; Framingham Risk Score (FRS) was 13.38 for the intervention group and 14.08 for the control group (p = 0.047) and SCORE was 1.69 vs. 1.82 (p = 0.022). The effect observed at 1-year was sustained over 3 years after adjustment for sex and education and more pronounced among participants with a severe atherosclerotic picture at baseline. CONCLUSIONS: This study provides evidence of sustained beneficial effects on the adherence to prevention guidelines over 3 years of pictorial information about subclinical carotid atherosclerosis, resulting in lower cardiovascular risk regardless of sex and educational level. Direct visualization of the underlying still subclinical atherosclerotic disease, rather than just indirect information about risk factors and statistical risk of future myocardial infarction, stroke and death, is one way to tackle the problem of non-adherence to prevention of cardiovascular diseases. |
format | Online Article Text |
id | pubmed-8387279 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-83872792021-10-04 The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial Bengtsson, Anna Norberg, Margareta Ng, Nawi Carlberg, Bo Grönlund, Christer Hultdin, Johan Lindahl, Bernt Lindahl, Bertil Nordin, Steven Nyman, Emma Wennberg, Patrik Wester, Per Näslund, Ulf Am J Prev Cardiol Original Research Contribution OBJECTIVE: Non-adherence to guidelines and preventive measures is a major challenge, particularly so to obtain long-term adherence to lifestyle changes and recommended medication. The objective was to investigate if pictorial information regarding subclinical carotid atherosclerosis provided to individuals and physicians gave sustained effects on cardiovascular risk beyond the previously reported effect after 1 year and up to 3 years. METHODS: A Prospective Randomized Open Blinded End-point (PROBE) trial. Within a CVD prevention program in Västerbotten County, Sweden, 3532 healthy individuals aged 40, 50 or 60 years were enrolled and 1:1 randomized to intervention (n = 1749; pictorial information with additional prevention materials to participants and physicians) or control group (n = 1783; no pictorial information to participants and physicians). Preventive measures were managed within primary care. Participants were investigated at baseline during 2013–2016 and at follow-up after 1 and 3 years. RESULTS: A beneficial effect on cardiovascular risk was observed at 3-year follow-up; Framingham Risk Score (FRS) was 13.38 for the intervention group and 14.08 for the control group (p = 0.047) and SCORE was 1.69 vs. 1.82 (p = 0.022). The effect observed at 1-year was sustained over 3 years after adjustment for sex and education and more pronounced among participants with a severe atherosclerotic picture at baseline. CONCLUSIONS: This study provides evidence of sustained beneficial effects on the adherence to prevention guidelines over 3 years of pictorial information about subclinical carotid atherosclerosis, resulting in lower cardiovascular risk regardless of sex and educational level. Direct visualization of the underlying still subclinical atherosclerotic disease, rather than just indirect information about risk factors and statistical risk of future myocardial infarction, stroke and death, is one way to tackle the problem of non-adherence to prevention of cardiovascular diseases. Elsevier 2021-05-21 /pmc/articles/PMC8387279/ /pubmed/34611639 http://dx.doi.org/10.1016/j.ajpc.2021.100199 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Contribution Bengtsson, Anna Norberg, Margareta Ng, Nawi Carlberg, Bo Grönlund, Christer Hultdin, Johan Lindahl, Bernt Lindahl, Bertil Nordin, Steven Nyman, Emma Wennberg, Patrik Wester, Per Näslund, Ulf The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial |
title | The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial |
title_full | The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial |
title_fullStr | The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial |
title_full_unstemmed | The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial |
title_short | The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial |
title_sort | beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: results from the vipviza randomized clinical trial |
topic | Original Research Contribution |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387279/ https://www.ncbi.nlm.nih.gov/pubmed/34611639 http://dx.doi.org/10.1016/j.ajpc.2021.100199 |
work_keys_str_mv | AT bengtssonanna thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT norbergmargareta thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT ngnawi thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT carlbergbo thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT gronlundchrister thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT hultdinjohan thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT lindahlbernt thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT lindahlbertil thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT nordinsteven thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT nymanemma thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT wennbergpatrik thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT westerper thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT naslundulf thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT bengtssonanna beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT norbergmargareta beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT ngnawi beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT carlbergbo beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT gronlundchrister beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT hultdinjohan beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT lindahlbernt beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT lindahlbertil beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT nordinsteven beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT nymanemma beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT wennbergpatrik beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT westerper beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial AT naslundulf beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial |